olivLaw · US equity research
AdaptHealth Corp. AHCO
Services-Home Health Care Services · SIC 8082 · Vertical: Services-Home Health Care Services (SIC 8082)
AdaptHealth Corp. provides home medical equipment, supplies and related services to patients across the United States, focused on sleep, respiratory and home wellness care. In 2026 it is concentrating its portfolio by agreeing to sell its Diabetes Health business, while Q2 2026 net revenue rose 12.7% to 740.3 million USD.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, AdaptHealth Corp. (AHCO) stock was 7.31 USD (+16.40% on the day), with market capitalisation 998.0 m USD, beta 0.71, 52-week range 5.22–13.38 USD. Latest reported quarter (Q3 2026): revenue of 745.6 m USD (+10.9% YoY), net income of -154.0 m USD (−728.3% YoY), diluted EPS -1.13 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 72.5
- overbought (≥ 70)
- Bollinger (20, 2)
- 5.50 – 6.75
- above the upper band · %B 1.44 · band width 20.4%
- SMA 50 / 200
- 5.93 / 9.15
- mixed trend
- MACD (12, 26, 9)
- 0.10 / 0.01
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +27.4% | −1.1% | +28.4 pp | — |
| 3 months | +12.5% | −0.5% | +13.0 pp | — |
| 6 months | −36.0% | +4.4% | −40.4 pp | — |
| Year to date | −26.6% | +12.3% | −38.9 pp | — |
| 1 year | −31.5% | +13.5% | −45.0 pp | +24.9% |
| 3 years | −13.7% | +76.4% | −90.1 pp | +26.6% |
| 5 years | −70.7% | +63.7% | −134.4 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 856.6 m | 777.9 m | 657.1 m | 672.4 m | 1.3 bn | 819.8 m | 740.3 m | 745.6 m |
| Cost of revenue | 664.4 m | 657.4 m | 521.3 m | 533.8 m | 1.0 bn | 708.3 m | 636.1 m | 630.8 m |
| Operating income | 97.7 m | 23.2 m | 65.7 m | 43.4 m | -31.6 m | 5.5 m | -137.8 m | -155.9 m |
| Depreciation & amortisation | 90.5 m | 94.3 m | 92.4 m ≈ | 97.7 m ≈ | 97.5 m | 106.5 m | 120.3 m ≈ | 116.9 m ≈ |
| Interest expense | 27.8 m | — | — | — | — | — | — | — |
| Pre-tax income | 70.7 m | -5.2 m | 38.2 m | 18.0 m | -56.3 m | -20.1 m | -165.3 m | -184.5 m |
| Income tax | 19.3 m | 850.0 k | 32.8 m | 6.5 m | 14.1 m | -5.2 m | -21.2 m | -17.5 m |
| Net income | 50.3 m | -7.2 m | 14.7 m | 24.5 m | -102.8 m | -16.0 m | -133.9 m | -154.0 m |
| Diluted EPS | 0.37 ≈ | -0.05 | 0.10 | 0.17 | -0.79 ≈ | -0.12 | -0.99 | -1.13 |
| Operating cash flow | 150.4 m | 95.5 m | 162.0 m ≈ | 161.1 m ≈ | 183.2 m | 93.7 m | 145.3 m ≈ | 156.6 m ≈ |
| Capex | 77.3 m | 95.6 m | 88.7 m ≈ | 94.2 m ≈ | 103.9 m | 121.2 m | 166.2 m ≈ | 105.5 m ≈ |
| Share repurchases | 0 | — | — | — | — | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 345.3 m | 529.6 m | 1.1 bn | 2.5 bn | 3.0 bn | 3.2 bn | 3.3 bn | 3.2 bn |
| Revenue YoY | unavailable | +53.4% | +99.5% | +132.4% | +21.0% | +7.7% | +1.9% | −0.5% |
| Net income | 23.3 m | -21.3 m | -161.6 m | 156.2 m | 69.3 m | -678.9 m | 90.4 m | -70.8 m |
| Net income YoY | unavailable | −191.7% | unavailable | unavailable | −55.6% | −1,079.4% | unavailable | −178.3% |
| Diluted EPS | unavailable | -0.95 | -3.08 | 0.67 | 0.33 | -5.31 | 0.61 | -0.52 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | −50.7% | −1,709.1% | unavailable | −185.2% |
| net % | 6.7% | -4.0% | -15.3% | 6.4% | 2.3% | -21.2% | 2.8% | -2.2% |
| Free cash flow | 58.5 m | 39.1 m | 155.9 m | 72.4 m | -17.6 m | 143.2 m | 235.8 m | 219.4 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 106.1 m USD
- Financial debt
- 1.7 bn USD
- Net debt
- 1.6 bn USD
- Equity
- 1.5 bn USD
- Total assets
- 4.3 bn USD
- Debt / equity
- 1.14x
- Current ratio
- 1.02x
- ROE
- -4.6%
- ROA
- -1.6%
- FCF margin
- 6.8%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 1.1 bn | 2.5 bn | 3.0 bn | 3.2 bn | 3.3 bn | 3.2 bn | SEC (XBRL)· 24 Feb 2026verified |
| Cost of revenue | 898.6 m | 2.0 bn | 2.4 bn | 2.6 bn | 2.6 bn | 2.6 bn | SEC (XBRL)· 24 Feb 2026verified |
| Gross profit | 157.8 m ≈ | 445.6 m ≈ | 580.1 m ≈ | 624.1 m ≈ | 681.1 m ≈ | 609.2 m ≈ | SEC (XBRL)· 24 Feb 2026derived |
| Operating income | 71.3 m | 225.6 m | 190.4 m | -598.4 m | 263.7 m | 90.9 m | SEC (XBRL)· 24 Feb 2026verified |
| Depreciation & amortisation | 82.4 m | 258.1 m | 351.2 m | 382.8 m | 365.3 m | 381.9 m | SEC (XBRL)· 24 Feb 2026verified |
| EBITDA | 153.8 m ≈ | 483.7 m ≈ | 541.6 m ≈ | -215.6 m ≈ | 629.1 m ≈ | 472.8 m ≈ | SEC (XBRL)· 24 Feb 2026derived |
| Interest expense | 41.4 m | 95.2 m | 109.4 m | 130.3 m | 124.7 m | 103.6 m | SEC (XBRL)· 24 Feb 2026verified |
| Pre-tax income | -206.0 m | 191.0 m | 97.9 m | -723.8 m | 136.0 m | -15.2 m | SEC (XBRL)· 24 Feb 2026verified |
| Income tax | -12.0 m | 32.8 m | 24.8 m | -49.0 m | 41.2 m | 50.9 m | SEC (XBRL)· 24 Feb 2026verified |
| Net income | -161.6 m | 156.2 m | 69.3 m | -678.9 m | 90.4 m | -70.8 m | SEC (XBRL)· 24 Feb 2026verified |
| Diluted EPS | -3.08 | 0.67 | 0.33 | -5.31 | 0.61 | -0.52 | SEC (XBRL)· 24 Feb 2026verified |
| Weighted average diluted shares | 52.5 m | 133.0 m | 139.0 m | 134.4 m | 135.5 m | 135.1 m | SEC (XBRL)· 24 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 100.0 m | 149.6 m | 46.3 m | 77.1 m | 109.7 m | 106.1 m | SEC (XBRL)· 24 Feb 2026verified |
| Receivables | 171.1 m | 359.9 m | 359.1 m | 388.9 m | 408.0 m | 370.9 m | SEC (XBRL)· 24 Feb 2026verified |
| Inventories | 58.8 m | 123.1 m | 127.8 m | 113.6 m | 139.8 m | 114.9 m | SEC (XBRL)· 04 Aug 2026verified |
| Current assets | 363.3 m | 670.1 m | 585.3 m | 649.0 m | 755.8 m | 728.9 m | SEC (XBRL)· 24 Feb 2026verified |
| Property, plant & equipment, net | 110.5 m | 398.6 m | — | 495.1 m | 474.6 m | 503.2 m | SEC (XBRL)· 04 Aug 2026verified |
| Goodwill | 998.8 m | 3.5 bn | 3.5 bn | 2.7 bn | 2.7 bn | 2.5 bn | SEC (XBRL)· 04 Aug 2026verified |
| Intangibles (excl. goodwill) | 116.1 m | 202.2 m | 162.8 m | 130.2 m | 105.5 m | 35.8 m | SEC (XBRL)· 04 Aug 2026verified |
| Total assets | 1.8 bn | 5.3 bn | 5.2 bn | 4.5 bn | 4.5 bn | 4.3 bn | SEC (XBRL)· 24 Feb 2026verified |
| Accounts payable | 191.0 m | 248.0 m | 222.5 m | 211.5 m | 281.9 m | 352.4 m | SEC (XBRL)· 24 Feb 2026verified |
| Short-term debt | 8.1 m | 20.0 m | 35.0 m | 53.4 m | 16.3 m | 20.3 m | SEC (XBRL)· 24 Feb 2026verified |
| Long-term debt | 776.6 m | 2.2 bn | 2.2 bn | 2.1 bn | 2.0 bn | 1.7 bn | SEC (XBRL)· 24 Feb 2026verified |
| Current liabilities | 422.1 m | 499.8 m | 456.2 m | 537.0 m | 567.0 m | 712.4 m | SEC (XBRL)· 24 Feb 2026verified |
| Total liabilities | 1.5 bn | 3.2 bn | 3.1 bn | 3.0 bn | 2.9 bn | 2.8 bn | SEC (XBRL)· 24 Feb 2026verified |
| Equity | 280.8 m | 2.1 bn | 2.2 bn | 1.5 bn | 1.6 bn | 1.5 bn | SEC (XBRL)· 24 Feb 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 195.6 m | 275.7 m | 373.9 m | 480.7 m | 541.8 m | 601.8 m | SEC (XBRL)· 24 Feb 2026verified |
| Capex | 39.8 m | 203.3 m | 391.4 m | 337.5 m | 306.1 m | 382.4 m | SEC (XBRL)· 24 Feb 2026verified |
| Free cash flow | 155.9 m ≈ | 72.4 m ≈ | -17.6 m ≈ | 143.2 m ≈ | 235.8 m ≈ | 219.4 m ≈ | SEC (XBRL)· 24 Feb 2026derived |
| Investing cash flow | -815.7 m | -1.8 bn | -411.2 m | -357.3 m | -310.3 m | -303.2 m | SEC (XBRL)· 24 Feb 2026verified |
| Financing cash flow | 643.2 m | 1.6 bn | -66.1 m | -92.5 m | -198.9 m | -302.2 m | SEC (XBRL)· 24 Feb 2026verified |
| Share repurchases | 0 | 0 | 14.0 m | 29.3 m | 0 | 0 | SEC (XBRL)· 24 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 39.6% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 998.0 m USD
Key indicators
Coverage and freshness
Score by group
40% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 39.6% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -11.4% | 0 (vs peers) | 16% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 3.0% | 25 (on a fixed band) | 21% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -3.1x | 0 (on a fixed band) | 16% |
| Current ratio · Balance sheet | 1.1x | 27 (on a fixed band) | 11% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 8.2% | 100 (on a fixed band) | 21% |
| Shareholder yield (distributions) · Returns | 0.0% | 0 (on a fixed band) | 16% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet11/100 · 2/3 factors with a value
- Growth· partial25/100 · 1/2 factors with a value
- Quality· partial0/100 · 1/3 factors with a value
- Returns· partial0/100 · 1/2 factors with a value
- Valuation· partial100/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
AdaptHealth Corp. (AHCO). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 3.2 bn USD in 2025; YoY growth -0.5%; net margin -11.4%; ROE -28.6%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (score weight coverage: 39.6% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- FCF yield: 8.2%
What contradicts it
- Net margin: -11.4%
- Revenue CAGR 3Y: 3.0%
- Interest coverage: -3.1x
- Current ratio: 1.1x
- Shareholder yield (distributions): 0.0%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Payout ratio (FCF).
Versus the vertical median
Services-Home Health Care Services (SIC 8082) · same industry (4-digit SIC) · compared with 5 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| BTSGBrightSpring Health Services, Inc. | 13.9 bn | 37.8 | 20.5% | 2.7% | +28.2% | +93% / unavailable |
| CHEChemed Corporation | 7.1 bn | 26.2 | 29.1% | 10.6% | +4.1% | +25% / −3% |
| OPCHOption Care Health, Inc. | 4.7 bn | 22.8 | 16.0% | 3.7% | +13.0% | +2% / +6% |
| AVAHAveanna Healthcare Holdings Inc. | 3.1 bn | 11.6 | 199.6% | 10.6% | unavailable | +52% / +421% |
| ADUSAddus HomeCare Corp | 2.4 bn | 21.3 | 10.0% | 7.4% | +23.2% | +6% / +47% |
| AHCOAdaptHealth Corp. | 998.0 m | — | -28.6% | -11.4% | −0.5% | −31% / −14% |
1- and 3-year price returns: for AHCO from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 04 Aug 2026; since then the company filed 8-K (03 Nov 2026 · results), 10-Q (03 Nov 2026).
In brief
AdaptHealth Corp. provides home medical equipment, supplies and related services to patients across the United States, focused on sleep, respiratory and home wellness care. In 2026 it is concentrating its portfolio by agreeing to sell its Diabetes Health business, while Q2 2026 net revenue rose 12.7% to 740.3 million USD 3.
SWOT
Strengths
- An integrated technology platform, a national location network, strong referral relationships and a diversified range of equipment and consumables 1.
- Strong organic growth in the second quarter of 2026, supported by new capitated contracts and digital expansion of services 3.
- Portfolio clarification through the planned sale of a business and a focus on core segments 3.
Weaknesses
- Reliance on a small number of suppliers for most equipment and consumables exposes the company to price and delivery shocks 1.
- Capitated contracts where care costs can exceed fixed revenue have already weighed on margins in 2026 3.
- Large goodwill write-downs signal difficulty in realising value from past acquisitions 3.
Opportunities
Risks
- Goodwill impairmenthigh
A further goodwill write-down could weigh on net income if the performance of reporting units weakens 3.
- Cybersecurity incidenthigh
Unauthorised access to systems holding patient data could lead to litigation, penalties and unforeseen costs, although the company says a material impact is not reasonably likely 2.
- Supplier dependencemedium
Price increases or disruption at key suppliers could reduce margins, as a manufacturer price rise already did in 2026 3.
- Capitated contract riskmedium
If care costs exceed fixed payments, results could be hurt, as the West Coast contract difficulties showed 3.
- Refinancing and debtlow
If refinancing is not achieved on terms as favourable as before, interest costs could rise 1.
Investment thesis
What would need to be true (bull case)
- If organic growth holds and restructuring lowers costs, the company could recover margin in its core segments 3.
- The Diabetes Health sale could simplify the portfolio and provide cash to reduce debt 2.
- Digital platform growth and myAPP user gains could support patient retention and operating efficiency 3.
What would break the thesis
- If the revised outlook reflects persistent cost pressure, margins could stay below expectations 3.
- Dependence on complex capitated contracts and a limited supplier base could amplify operational shocks 1.
- The cybersecurity incident and any resulting penalties could generate unforeseen costs over the medium term 2.
What to watch
- Closing of the Diabetes Health sale and use of proceedsQ1 2027
- Actual effect of restructuring on costs and margins2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 04 Aug 2026; since then the company filed 8-K (03 Nov 2026 · results), 10-Q (03 Nov 2026).
The business
Revenue combines one-time sales of consumables, fixed monthly equipment reimbursements and at-risk capitation contracts, under which the company receives a fixed amount per member and bears the cost of care 1. Growth has come from acquisitions and new capitated contracts, and a large West Coast contract reached full run-rate in the second quarter of 2026 3.
Segments
Sleep Health
The segment supplies equipment and consumables for obstructive sleep apnea, including CPAP and BiLevel services, and was the largest net sales revenue line in fiscal 2025 at about 1,040.4 million USD 1. It is kept as a core business after the Diabetes Health sale 3.
Market context
The US home medical equipment market is fragmented and highly competitive, and consolidation continues because technology investment and reimbursement cuts pressure smaller providers 1. Larger providers with integrated technology could gain share as a result 1.
Demand depends on Medicare, Medicaid and private insurer reimbursement, and on referrals from hospitals, sleep labs and pulmonology practices 1. Federal and state regulation is strict, and non-compliance can bring significant penalties 1.
Trends
- Consolidation of the HME markettailwind
Financial pressure on smaller providers and the advantage of large automated operators could favour companies like AdaptHealth in acquisitions and share gains 1.
- Inflation and cost pressureheadwind
Higher costs for materials, labour, shipping and fuel, including effects of the war with Iran on fuel prices, could compress margins if they cannot be passed on to customers 2.
- Labour shortages and union activityheadwind
Shortages of qualified staff and wage pressure could raise operating costs, and union activity could add further pressure 1.
- Wider sleep apnea diagnosismixed
Adding home sleep testing could help reach a large undiagnosed population if the new partnership meets its goals 3.
Competitive position
AdaptHealth competes with large national providers such as Lincare, Rotech, Cardinal Health and Quipt Home Medical, with regional providers such as DASCO, Viemed and Protech, and with product-specific providers such as Inogen and CCS Medical 1. It also competes with non-HME players such as CVS and Amazon 1.
The key factors are quality of care, referral process efficiency, technology platform, reputation with physicians, payor contracts and ease of doing business 1. The company says it competes favourably on these factors 1.
- Lincare Holdings
National home respiratory equipment provider named by the company as a direct HME competitor 1.
- Rotech Healthcare
National home medical equipment provider competing in respiratory and sleep categories 1.
- Cardinal Health
Large medical distribution company that competes in delivering home equipment and supplies 1.
- Quipt Home Medical
National home medical equipment provider competing in the respiratory segment 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- 4.1 Million Impacted by AdaptHealth Data BreachSecurityWeek · 10 Sept 2026 · EN
- AdaptHealth confirms 4.1 million people exposed in July cyberattackBleepingComputer · 09 Sept 2026 · EN
- AdaptHealth says attackers sweet-talked their way into cloud systems and stole patient dataThe Register · 03 Jul 2026 · RO
The latest news item in our archive is from 10 Sept 2026; the newest SEC filing is from 03 Nov 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report03 Nov 2026
- Current report03 Nov 2026Results of operations · Financial statements and exhibits
- Current report08 Sept 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report04 Aug 2026
- Current report04 Aug 2026Results of operations · Financial statements and exhibits
- Current report20 Jul 2026Material agreement · Financial statements and exhibits
- Current report07 Jul 2026Regulation FD disclosure
- Current report02 Jul 2026Material cybersecurity incident
- Current report22 Jun 2026Shareholder vote
- Current report (amendment)02 Jun 2026Departure or appointment of officers · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / AdaptHealth Corp. · 24 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / AdaptHealth Corp. · 04 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / AdaptHealth Corp. · 04 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.